CDT Equity Shares Set to Reverse Split on Monday, July 20th (NASDAQ:CDT)

CDT Equity Inc. (NASDAQ:CDT)’s stock is going to reverse split on Monday, July 20th. The 1-10 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Sunday, July 19th.

CDT Equity Stock Up 1.1%

NASDAQ CDT traded up $0.00 during trading on Thursday, hitting $0.35. The company had a trading volume of 888,099 shares, compared to its average volume of 19,030,332. CDT Equity has a one year low of $0.30 and a one year high of $461.54. The company’s fifty day moving average is $0.92 and its 200-day moving average is $12.33.

CDT Equity (NASDAQ:CDT) last posted its earnings results on Wednesday, July 15th. The company reported ($5.56) EPS for the quarter.

Analysts Set New Price Targets

A number of research analysts have weighed in on CDT shares. Wall Street Zen downgraded CDT Equity to a “strong sell” rating in a report on Saturday, June 27th. Weiss Ratings restated a “sell (e+)” rating on shares of CDT Equity in a research note on Wednesday, June 24th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, CDT Equity presently has a consensus rating of “Sell”.

CDT Equity Company Profile

Conduit Pharmaceuticals Inc, a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.